Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies
Sponsor: Madrigal Pharmaceuticals, Inc.
A observational or N/A phase clinical study on MASH - Metabolic Dysfunction-Associated Steatohepatitis, this trial is actively recruiting participants. The trial is conducted by Madrigal Pharmaceuticals, Inc. and has accumulated 2 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
2 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
Status: Active Not Recruiting → Recruiting · Phase: PHASE2 → None
-
Feb 2026 — May 2026 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Contact Information
- Madrigal Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .